20 Sep 2012 07:00
FOR IMMEDIATE RELEASE | 20 September 2012 |
ImmuPharma PLC
Notification of Interim Results
Date: Wednesday 26 September 2012
ImmuPharma PLC (AIM:IMM), the specialist discovery and development pharmaceutical company, is scheduled to announce its Interim Results for the six months ended 30 June 2012 on Wednesday 26 September 2012.
For analysts who would like an update meeting with ImmuPharma's management team following the announcement of the results, please contact Lisa Baderoon, Head of Investor Relations, at the contact details given below.
Ends
For further information, please contact:
ImmuPharma plc | + 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer | + 44 (0) 20 7152 4080 |
Richard Warr, Chairman | |
Lisa Baderoon, Head of Investor Relations lisa.baderoon@immupharma.com | + 44 (0) 7721 413496 |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court | |
Panmure, Gordon & Co., NOMAD & Broker | +44 (0) 20 7459 3600 |
Andrew Burnett | |
Fred Walsh | |
Espirito Santo Investment Bank, Joint Broker | +44 (0) 20 7456 9191 |
James Bromhead | |
Richard Crawley | |
Cenkos Securities plc, Joint Broker | +44 (0) 20 7397 8900 |
Stephen Keys, Camilla Hume (Corporate Finance) | |
Andy Roberts (Sales) |
Immupharma (IMM)